骨髓瘤细胞衍生微泡的检测：一种监测多发性骨髓瘤负荷的工具。
Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load.
作者信息
Liu Zhao-Yun, Meng Nan-Hao, Cao Pan-Pan, Peng Feng-Ping, Luo Jing-Yi, Wang Hao, Jiang Feng-Juan, Lu Jin, Fu Rong
机构信息
Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Heping District, Tianjin, 300052, People's Republic of China.
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, 100044, People's Republic of China.
出版信息
Exp Hematol Oncol. 2023 Mar 6;12(1):26. doi: 10.1186/s40164-023-00392-4.
The persistence of tumor load in multiple myeloma (MM) lead to relapse in patients achieving complete remission (CR). Appropriate and effective methods of myeloma tumor load monitoring are important for guiding clinical management. This study aimed to clarify the value of microvesicles in monitoring MM tumor load. Microvesicles in bone marrow and peripheral blood were isolated by differential ultracentrifugation and detected by flow cytometry. Western blotting was applied to assess myosin light chain phosphorylation levels. Flow cytometry to detect PsCD41a, PsCD41aCD138, PsCD41aBCMA microvesicles from bone marrow can be used to predict myeloma burden, furthermore, PsCD41a microvesicles may as a potential index to MRD test. Mechanistically, the releasing of microvesicles from MM cell was regulated by Pim-2 Kinase via Phosphorylation of MLC-2 protein.
多发性骨髓瘤（MM）患者体内肿瘤负荷的持续存在会导致达到完全缓解（CR）的患者复发。合适且有效的骨髓瘤肿瘤负荷监测方法对于指导临床管理至关重要。本研究旨在阐明微泡在监测MM肿瘤负荷中的价值。通过差速超速离心法分离骨髓和外周血中的微泡，并采用流式细胞术进行检测。应用蛋白质免疫印迹法评估肌球蛋白轻链磷酸化水平。流式细胞术检测骨髓来源的PsCD41a、PsCD41aCD138、PsCD41aBCMA微泡可用于预测骨髓瘤负荷，此外，PsCD41a微泡可能作为微小残留病（MRD）检测的潜在指标。从机制上讲，MM细胞微泡的释放受Pim-2激酶通过MLC-2蛋白磷酸化的调控。
Zotero 插件